

**TABLE 7.1**  
**Insulin Products for Cats**

Insulin Product	Product Description	Brand Name (Manufacturer)	Veterinary FDA Approval Status	Peak Action (Nadir) and Duration of Effect	Starting Dose	Concentration
<b>Intermediate-Acting Insulin</b>						
<b>Lente</b>	Porcine insulin zinc suspension	<b>Vetsulin</b> (Merck Animal Health)	Approved	Nadir 2–8 hr. Duration 8–14 hr. <sup>a</sup>	1–2 U per cat q 12 hr. <sup>b</sup>	U-40
	<b>Comments:</b> <ul style="list-style-type: none"> <li>• Injection pens (in either 0.5-U or 1-U increments) are available for cats.</li> <li>• Bottle must be shaken to resuspend insulin crystals prior to use.</li> </ul>					
<b>Long-Acting Insulin</b>						
<b>Glargine U-100</b>	Recombinant DNA origin human insulin	<b>Lantus</b> (Sanofi)	Not approved	Nadir 12–14 hr. Duration 12–24 hr.	1–2 U per cat q 12 hr.	U-100
		<b>Basaglar</b> (Lilly) <b>Semglee</b> (Viatris & Biocon Biologics) <b>Glargine yfgn</b> (Viatris & Biocon Biologics) <b>Rezvoglar</b> (Lilly)				
<b>Comments:</b> Commonly used in cats; use only U-100 (U-300 available; see below).						
<b>PZI</b>	Recombinant DNA origin human insulin	<b>ProZinc</b> (Boehringer Ingelheim Animal Health)	Approved	Nadir 5–7 hr. Duration 8–24 hr. <sup>c</sup>	1–2 U per cat q 12 hr.	U-40
<b>Comments:</b> Commonly used in cats.						
<b>Basal Insulin</b>						
<b>Degludec</b>	Recombinant DNA origin human insulin	<b>Tresiba</b> (Novo Nordisk)	Not approved	Peakless Duration 10.35 +/- 3 hr. <sup>d</sup>	1 U per cat q 12 hr. <sup>e</sup>	U-100, U-200
<b>Comments:</b> <ul style="list-style-type: none"> <li>• Duration in cats suggests use as a q 12 hr insulin.</li> <li>• Does not need to be given with a meal.</li> </ul>						
<b>Glargine U-300</b>	Recombinant DNA origin human insulin	<b>Toujeo</b> (Sanofi)	Not approved	Peakless Duration 14.5 +/- 2.3 hr. <sup>d</sup>	0.5 U/kg q 12–24 hr. <sup>f</sup>	U-300
					Or 2 U per cat q 24 hr. <sup>e</sup>	
<b>Comments:</b> <ul style="list-style-type: none"> <li>• Use lean body weight to calculate U/kg doses.</li> <li>• Does not need to be given with a meal.</li> <li>• Requires administration using the manufacturer-provided prefilled insulin pen in increments of 1 unit.</li> </ul>						

BG, blood glucose; PZI, protamine zinc insulin; U, units.

- Martin GJ, Rand JS. Pharmacokinetic and pharmacodynamics study of caninsulin in cats with diabetes mellitus. Internal Study Report. 2000.
- Caney SM. Management of cats on Lente insulin: tips and traps. *Vet Clin North Am Small Anim Pract* 2013;43(2):267–82.
- Nelson RW, Henley K, Cole C, et al. Field safety and efficacy of protamine zinc recombinant human insulin for treatment of diabetes mellitus in cats. *J Vet Intern Med* 2009;23(4):787–93.
- Gilor C, Culp W, Ghandi S, et al. Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats. *Domest Anim Endocrinol* 2019;69:19–29.
- Gilor C, Fleeman LM. One hundred years of insulin: Is it time for smart? *J Small Anim Pract* 2022;63(9):645–60.
- Linari G, Fleeman L, Gilor C, et al. Insulin glargine 300 U/ml for the treatment of feline diabetes mellitus. *J Feline Med Surg* 2022;24(2):168–76.

**The 2026 AAHA Diabetes Management Guidelines for Cats are available at [aaha.org/diabetes-management-cats](http://aaha.org/diabetes-management-cats)**

These guidelines were prepared by a Task Force of experts convened by the American Animal Hospital Association (AAHA) and were subjected to a formal peer-review process. This document is intended as a guideline only, not an AAHA standard of care. These guidelines and recommendations should not be construed as dictating an exclusive protocol, course of treatment, or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to each individual practice setting. ©2026 AAHA.

